title: Importance of transparency in assessing the feasibility of modeling rare disease.
authors.affiliation: Medicus Economics, Milton, MA (SJJ)
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Johnson
authors.affiliation: Medicus Economics, LLC, Brookline, MA (MRD)
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Davis
authors.affiliation: Medicus Economics, Cambridge, MA (STW)
authors.forename: Si-Tien
authors.initials: ST
authors.lastname: Wang
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006801:Humans; D035583:Rare Diseases / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized